Vasodilator Therapies in the Treatment of Acute Heart Failure

Daniel B. Holt, Peter Pang

Research output: Contribution to journalReview article

Abstract

Purpose of Review: Vasodilators are commonly recommended to treat acute heart failure (AHF), yet they are infrequently used. This review aims to evaluate the clinical utility of traditional, historical, and novel vasodilators in the treatment of AHF. Recent Findings: No traditional vasodilator (i.e., nitroglycerin) therapy definitely improves short- or long-term outcomes. Despite repeated efforts to develop new pharmacologic treatments, no novel therapy outperforms traditional management. At the present time, we continue to recommend traditional vasodilators, such as nitroglycerin. Summary: The use of select vasodilators in the treatment of AHF improves hemodynamics and provides short-term relief; however, data regarding long-term benefits is lacking.

Original languageEnglish (US)
Pages (from-to)32-37
Number of pages6
JournalCurrent Heart Failure Reports
Volume16
Issue number1
DOIs
StatePublished - Feb 15 2019

Fingerprint

Vasodilator Agents
Heart Failure
Nitroglycerin
Therapeutics
Hemodynamics

Keywords

  • Acute heart failure
  • Vasodilator(s)

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Emergency Medicine

Cite this

Vasodilator Therapies in the Treatment of Acute Heart Failure. / Holt, Daniel B.; Pang, Peter.

In: Current Heart Failure Reports, Vol. 16, No. 1, 15.02.2019, p. 32-37.

Research output: Contribution to journalReview article

@article{ae73037e3e884f57b86bcca3b7f9ee57,
title = "Vasodilator Therapies in the Treatment of Acute Heart Failure",
abstract = "Purpose of Review: Vasodilators are commonly recommended to treat acute heart failure (AHF), yet they are infrequently used. This review aims to evaluate the clinical utility of traditional, historical, and novel vasodilators in the treatment of AHF. Recent Findings: No traditional vasodilator (i.e., nitroglycerin) therapy definitely improves short- or long-term outcomes. Despite repeated efforts to develop new pharmacologic treatments, no novel therapy outperforms traditional management. At the present time, we continue to recommend traditional vasodilators, such as nitroglycerin. Summary: The use of select vasodilators in the treatment of AHF improves hemodynamics and provides short-term relief; however, data regarding long-term benefits is lacking.",
keywords = "Acute heart failure, Vasodilator(s)",
author = "Holt, {Daniel B.} and Peter Pang",
year = "2019",
month = "2",
day = "15",
doi = "10.1007/s11897-019-0421-4",
language = "English (US)",
volume = "16",
pages = "32--37",
journal = "Current Alzheimer Research",
issn = "1546-9530",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Vasodilator Therapies in the Treatment of Acute Heart Failure

AU - Holt, Daniel B.

AU - Pang, Peter

PY - 2019/2/15

Y1 - 2019/2/15

N2 - Purpose of Review: Vasodilators are commonly recommended to treat acute heart failure (AHF), yet they are infrequently used. This review aims to evaluate the clinical utility of traditional, historical, and novel vasodilators in the treatment of AHF. Recent Findings: No traditional vasodilator (i.e., nitroglycerin) therapy definitely improves short- or long-term outcomes. Despite repeated efforts to develop new pharmacologic treatments, no novel therapy outperforms traditional management. At the present time, we continue to recommend traditional vasodilators, such as nitroglycerin. Summary: The use of select vasodilators in the treatment of AHF improves hemodynamics and provides short-term relief; however, data regarding long-term benefits is lacking.

AB - Purpose of Review: Vasodilators are commonly recommended to treat acute heart failure (AHF), yet they are infrequently used. This review aims to evaluate the clinical utility of traditional, historical, and novel vasodilators in the treatment of AHF. Recent Findings: No traditional vasodilator (i.e., nitroglycerin) therapy definitely improves short- or long-term outcomes. Despite repeated efforts to develop new pharmacologic treatments, no novel therapy outperforms traditional management. At the present time, we continue to recommend traditional vasodilators, such as nitroglycerin. Summary: The use of select vasodilators in the treatment of AHF improves hemodynamics and provides short-term relief; however, data regarding long-term benefits is lacking.

KW - Acute heart failure

KW - Vasodilator(s)

UR - http://www.scopus.com/inward/record.url?scp=85061665169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061665169&partnerID=8YFLogxK

U2 - 10.1007/s11897-019-0421-4

DO - 10.1007/s11897-019-0421-4

M3 - Review article

VL - 16

SP - 32

EP - 37

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1546-9530

IS - 1

ER -